Shopping Cart (0)
My Account

Your Shopping Cart
Academic Discovery WorkshopAdvances in Plant Genomics - Online EventTranslational Regenerative Medicine Congress 2014ISEV2014 Educational EventBiofluid Biopsies and Companion Diagnostics 201420% Discount OfferePoster Award PrizeBlogs

Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

Publisher: Select Biosciences
Published: January 2011
Pages: 139

Price:



This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.

Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.

This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.

Extensive Worldwide Technical and Market Analyses Presented in this Report:

  • Classification and Characterization of Cancer Vaccines
  • Various Approaches for the Generation of Cancer Vaccines
  • Anti-Cancer Vaccination Strategies
  • Tumor Associated Antigens (TAAs)
  • Tumor Specific Antigens (TSAs)
  • Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
  • Strategies to Improve Success of Cancer Vaccines
  • US FDA-Approved Cancer Vaccines
  • Therapeutic Cancer Vaccines Approved in Various Countries Around the World
  • Cancer Vaccine Pipeline in Late-Stage Clinical Trials
  • Cancer Vaccine Pipeline in Early-Stage Clinical Trials
  • Pre-Clinical Cancer Vaccine Pipeline
  • Personalized Cancer Vaccination Strategies
  • Biology and Characteristics of CTCs
  • Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
  • More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report—see below for link to downloadable PDF of the TOC

Report Table of Contents (TOC) [Click Here to Download PDF File]


For enquiries about this market report, please contact Kathy Gray at Kathy.Gray@Selectbiosciences.com

Conference News
Site Visit to the SIMTech Microfluidics Foundry
Site Visit to the SIMTech Microfluidics Foundry
Take advantage of a tour of the facilities at the SIMTech Microfluidic Foundry. Dr. Zhiping Wang, Director of Research Programmes, will be your host, providing all attendees with a detailed insight into the advanced work carried out by SIMTech. Don't miss out - Register today!


LAB-ON-A-CHIP ASIA - EARLY BIRD
LAB-ON-A-CHIP ASIA - EARLY BIRD
SAVE UP TO S$150 - EARLY BIRD DEADLINE 10 OCTOBER 2014. Don't miss out - register today!


Keynote Speaker Confirmed, Stephen Minger
We are thrilled to announce that Stephen Minger, Global Director of GE Healthcare, has confirmed he will be giving a keynote presentation at Stem Cells in Drug Discovery 2015.


Accreditation
“The Medical Association of Saxony certificates the two-day congress with 16 continuing education points.”


Call for papers - Clinical Applications of Stem Cells 2015
Call for papers - Clinical Applications of Stem Cells 2015
We are now accepting papers for the Clinical Applications of Stem Cells meeting which will take place on the 26-27 of February 2015 in Singapore.


Keynote Speakers Confirmed, Carlos Caldas and Mark Caulfield
We are thrilled to announce that Professor Carlos Caldas, Group Leader at the Cancer Research UK Cambridge Institute and Professor Mark Caufield, Chief Scientist of the Genomics England 100,000 project, have both confirmed their keynote presentations at Personalized Medicine in May 2015, Cambridge.

Scroll Up
Scroll Down
Keep me updated Select Bio Blog LinkedIn Twitter LabTube.tv SBOnDemand.com MarketReports.com Research-Store.com